CLARIUS-MOBILE-HEALTH
5.5.2022 09:17:13 CEST | Business Wire | Press release
Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter and smaller, the new pocket-sized scanners that connect with Apple and Android devices are available today with revolutionary pricing and new features that will put premium handheld ultrasound into the hands of more doctors. Clarius has replaced the complex knobs and buttons found on traditional ultrasound systems with an app that uses artificial intelligence and intuitive touch-based controls. Thousands of first and second generation Clarius scanners are already in use across the continent to improve diagnostic speed and accuracy and improve procedural safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005072/en/
“Clinicians in Europe and the UK have been early adopters of Clarius wireless ultrasound, and we know excitement has been building for our new miniaturized Clarius HD3 because we’ve had a long list of customers eagerly waiting for CE certification,” says Clarius Founder Laurent Pelissier. “Our mission has always been to improve patient care by enabling more clinicians to use ultrasound. Now that Clarius is reduced to the size of an iPhone, easier to use, and costs less, we’re expecting more clinicians will use ultrasound to deliver the best patient care.”
In emergency environments, the Clarius C3 HD3 multipurpose scanner saves lives. Dr. Wolfgang Fleischmann, an anesthesiologist and emergency medicine physician, describes why the Red Cross chose Clarius when it sought to equip its emergency services vehicles with hospital-grade portable ultrasound.
“We had the opportunity to extensively test the Clarius scanner in our prehospital emergency environment. The product impressed us with its image quality, its reliability, its short start-up time, and good price-to-performance ratio. It prompted us to equip all our emergency doctors’ cars and ambulances with the Clarius ultrasound device.”
Clarius sets itself apart from other handheld ultrasound systems with exceptional imaging quality that rivals expensive cart-based systems, wireless connectivity, and specialty scanners with Software-as-a-Service (SaaS) designed to optimize clarity and workflows for different anatomy and applications. Clinicians can choose from seven ultrasound scanners, each designed to meet the specific requirements of a broad range of medical specialties.
With best-in-class MSK imaging, the Clarius L15 HD3 high-frequency linear scanner is a top choice amongst orthopaedic surgeons. Dr. Rudolf Berlakovits, MD, PhD, an orthopaedic surgeon in Vienna, Austria, describes the advantages of the new Clarius HD3 for safe, procedural guidance.
"To me as an orthopedic surgeon, the Clarius HD3 is a highly recommended device for interventional orthopedics and ultrasound guided orthopedic surgery. There is no cable, making it easy to keep aseptic, and the probe provides perfect handling. Another really great benefit is the possibility to share the findings with colleagues all over the world in real-time with Clarius Cloud exam management."
Clarius offers software packages designed for many specialty applications including Advanced Breast , Musculoskeletal , Obstetrics , Primary/Critical Care , Vascular , Veterinary Packages , and Aesthetics . They deliver dedicated presets, advanced workflows, comprehensive measurements, and fined tuned imaging, leveraging artificial intelligence and SaaS to deliver a complete handheld ultrasound solution that’s connected to the cloud.
Dr. Ines Verner, an Aesthetic Dermatologist based in Tel-Aviv, uses the Clarius L20 wireless ultrasound scanner to prevent complications such as vascular occlusions during aesthetic procedures like cosmetic fillers. She was among the first to try the Clarius L20 HD3 for facial aesthetics.
“It’s a breakthrough in the field. Clarius is a good fit for aesthetics because it lets me clearly see fine facial anatomy, it’s easy to use, the image quality is good, it’s wireless, and it’s small so I can take it with me from room to room,” Dr. Verner says. “Ultrasound is a gamechanger for the aesthetics industry because we can really see what we need to see instead of injecting blindly, which is what most of us used to do. Now, we can inject knowing where we’re going and not to inject where we don’t want to inject.”
New Membership Enables Ultrasound Mastery at a Lower Price
Clarius has introduced a new Clarius Membership bundle that makes the entry price lower and enables new users to fast-track ultrasound proficiency. Clarius HD3 wireless scanners now start at 2875 EUR with a 575 annual membership in Europe or 2440 GBP with 490 membership annual membership in the United Kingdom. Members gain access to all advanced SaaS, enhanced education options, and unlimited exam management in the Clarius Cloud. A three-year standard warranty is included with enhanced warranty options available through Clarius Care.
About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost. More than two million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005072/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
